Dabomb Protein
DaBomb Protein Biotech Corp. manufactures and sells hydrolyzed soy protein in Vietnam, the Philippines, South Korea, Taiwan, and Asia. It offers plant protein, including DaBomb-P (Aqua) and DaBomb-P (Livestock); antibiotics alternatives, such as DBT-100 HT and DBT-100 LS; and pet care products comprising Liqui-TIDE bandages. The company was formerly known as DaBomb Protein Corp. and changed its n… Read more
Dabomb Protein (6578) - Total Liabilities
Latest total liabilities as of June 2025: NT$198.79 Million TWD
Based on the latest financial reports, Dabomb Protein (6578) has total liabilities worth NT$198.79 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Dabomb Protein - Total Liabilities Trend (2015–2024)
This chart illustrates how Dabomb Protein's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Dabomb Protein Competitors by Total Liabilities
The table below lists competitors of Dabomb Protein ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mobileleader Co.Ltd
KQ:100030
|
Korea | ₩13.06 Billion |
|
Binero Group AB
ST:BINERO
|
Sweden | Skr272.30 Million |
|
FCS Software Solutions Limited
NSE:FCSSOFT
|
India | ₹361.42 Million |
|
YIHO International Co., Ltd.
TWO:7590
|
Taiwan | NT$4.76 Billion |
|
Micromem Technologies Inc
OTCQB:MMTIF
|
USA | $6.62 Million |
|
Jervois Mining Ltd
PINK:JRVMF
|
USA | $252.06 Million |
|
Invesque Inc
PINK:MHIVF
|
USA | $82.40 Million |
|
Genius Group Ltd
NYSE MKT:GNS
|
USA | $17.19 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Dabomb Protein's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dabomb Protein's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dabomb Protein (2015–2024)
The table below shows the annual total liabilities of Dabomb Protein from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$225.96 Million | -49.09% |
| 2023-12-31 | NT$443.83 Million | -19.72% |
| 2022-12-31 | NT$552.88 Million | -16.51% |
| 2021-12-31 | NT$662.24 Million | +85.68% |
| 2020-12-31 | NT$356.66 Million | +61.41% |
| 2019-12-31 | NT$220.96 Million | +68.18% |
| 2018-12-31 | NT$131.39 Million | -42.45% |
| 2017-12-31 | NT$228.29 Million | +14.08% |
| 2016-12-31 | NT$200.11 Million | +45.74% |
| 2015-12-31 | NT$137.31 Million | -- |